Literature DB >> 32289504

Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Shobini Jayaraman1, Olivia R Chavez2, Antonio Pérez3, Inka Miñambres4, Jose Luis Sánchez-Quesada5, Olga Gursky6.   

Abstract

Low-density lipoprotein (LDL) binding to arterial proteoglycans initiates LDL retention and modification in the arterial wall, triggering atherosclerosis. The details of this binding, its effectors, and its ramifications are incompletely understood. We combined heparin affinity chromatography with biochemical, spectroscopic and electron microscopic techniques to show that brief binding to heparin initiates irreversible pro-atherogenic remodeling of human LDL. This involved decreased structural stability of LDL and increased susceptibility to hydrolysis, oxidation and fusion. Furthermore, phospholipid hydrolysis, mild oxidation and/or glycation of LDL in vitro increase the proteolytic susceptibility of apoB and its heparin binding affinity, perhaps by unmasking additional heparin-binding sites. For LDL from hyperglycemic type-2 diabetic patients, heparin binding was particularly destabilizing and caused apoB fragmentation and LDL fusion. However, for similar patients whose glycemic control was restored upon therapy, LDL-heparin binding affinity was rectified and LDL structural stability was partially restored. These results complement previous studies of LDL binding to arterial proteoglycans and suggest that such interactions may produce a particularly pro-atherogenic subclass of electronegative LDL. In summary, binding to heparin alters apoB conformation, perhaps by partially peeling it off the lipid, and triggers pro-atherogenic LDL modifications including hydrolysis, oxidation, and destabilization. Furthermore, phospholipid lipolysis, mild oxidation and glycation of LDL in vitro strengthen its binding to heparin, which helps explain stronger binding observed in hyperglycemic LDL. Combined effects of hyperglycemia and heparin binding are especially deleterious but are largely rectified upon diabetes therapy. These findings help establish a mechanistic link between diabetes and atherosclerosis. Published by Elsevier B.V.

Entities:  

Keywords:  Glycemic control in diabetes and atherosclerosis; LDL hydrolysis, oxidation and glycation; Limited proteolysis; Lipoprotein remodeling and fusion; apoB conformation

Mesh:

Substances:

Year:  2020        PMID: 32289504      PMCID: PMC7269877          DOI: 10.1016/j.bbalip.2020.158712

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Biol Lipids        ISSN: 1388-1981            Impact factor:   4.698


  50 in total

1.  Kinetic analysis of thermal stability of human low density lipoproteins: a model for LDL fusion in atherogenesis.

Authors:  Mengxiao Lu; Donald L Gantz; Haya Herscovitz; Olga Gursky
Journal:  J Lipid Res       Date:  2012-07-31       Impact factor: 5.922

Review 2.  The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.

Authors:  Jan Borén; Kevin Jon Williams
Journal:  Curr Opin Lipidol       Date:  2016-10       Impact factor: 4.776

3.  Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans.

Authors:  Iris J Edwards; James G Terry; Audrey D Bell-Farrow; William T Cefalu
Journal:  Metabolism       Date:  2002-10       Impact factor: 8.694

4.  Increased retention of LDL from type 1 diabetic patients in atherosclerosis-prone areas of the murine arterial wall.

Authors:  Mette K Hagensen; Martin B Mortensen; Mads Kjolby; Johan Palmfeldt; Jacob F Bentzon; Soeren Gregersen
Journal:  Atherosclerosis       Date:  2019-03-04       Impact factor: 5.162

5.  Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins.

Authors:  Z S Ji; H L Dichek; R D Miranda; R W Mahley
Journal:  J Biol Chem       Date:  1997-12-12       Impact factor: 5.157

6.  Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation.

Authors:  Fredrik Noborn; John B Ancsin; Wimal Ubhayasekera; Robert Kisilevsky; Jin-Ping Li
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

Review 7.  Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis.

Authors:  Maged F Khalil; William D Wagner; Ira J Goldberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-07       Impact factor: 8.311

Review 8.  Hyperglycemia and the pathobiology of diabetic complications.

Authors:  Doron Aronson
Journal:  Adv Cardiol       Date:  2008

9.  Effects of oxidation on the structure and stability of human low-density lipoprotein.

Authors:  Shobini Jayaraman; Donald L Gantz; Olga Gursky
Journal:  Biochemistry       Date:  2007-04-20       Impact factor: 3.162

10.  Diabetes mellitus, fasting glucose, and risk of cause-specific death.

Authors:  Alexander Thompson; Emanuele Di Angelantonio; Pei Gao; Nadeem Sarwar; Sreenivasa Rao Kondapally Seshasai; Stephen Kaptoge; Peter H Whincup; Kenneth J Mukamal; Richard F Gillum; Ingar Holme; Inger Njølstad; Astrid Fletcher; Peter Nilsson; Sarah Lewington; Rory Collins; Vilmundur Gudnason; Simon G Thompson; Naveed Sattar; Elizabeth Selvin; Frank B Hu; John Danesh
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

View more
  1 in total

1.  Heparin binding triggers human VLDL remodeling by circulating lipoprotein lipase: Relevance to VLDL functionality in health and disease.

Authors:  Shobini Jayaraman; Antonio Pérez; Inka Miñambres; Jose Luis Sánchez-Quesada; Olga Gursky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-10-02       Impact factor: 4.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.